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Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the averagemagnitude
of these risks is uncertain and may depend on the context. Estimates based on multiple-case families may be enriched
for mutations of higher risk and/or other familial risk factors, whereas risk estimates from studies based on cases
unselected for family history have been imprecise. We pooled pedigree data from 22 studies involving 8,139 index
case patients unselected for family history with female (86%) or male (2%) breast cancer or epithelial ovarian
cancer (12%), 500 of whom had been found to carry a germline mutation in BRCA1 or BRCA2. Breast and ovarian
cancer incidence rates for mutation carriers were estimated using a modified segregation analysis, based on the
occurrence of these cancers in the relatives of mutation-carrying index case patients. The average cumulative risks
in BRCA1-mutation carriers by age 70 years were 65% (95% confidence interval 44%–78%) for breast cancer
and 39% (18%–54%) for ovarian cancer. The corresponding estimates for BRCA2 were 45% (31%–56%) and
11% (2.4%–19%). Relative risks of breast cancer declined significantly with age for BRCA1-mutation carriers (P
trend .0012) but not for BRCA2-mutation carriers. Risks in carriers were higher when based on index breast cancer
cases diagnosed at !35 years of age. We found some evidence for a reduction in risk in women from earlier birth
cohorts and for variation in risk by mutation position for both genes. The pattern of cancer risks was similar to those
found in multiple-case families, but their absolute magnitudes were lower, particularly for BRCA2. The variation in
risk by age at diagnosis of index case is consistent with the effects of other genes modifying cancer risk in carriers.
Introduction
Mutations in the breast and ovarian cancer–susceptibility
genes BRCA1 (MIM 113705) (Miki et al. 1994) and
BRCA2 (MIM 600185) (Wooster et al. 1995; Tavtigian
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et al. 1996) are found in a high proportion of multiple-
case families with breast cancer, especially if they also
include one or more case patients with ovarian cancer
(Ford et al. 1994). Screening for mutations in these genes
for predictive genetic testing has become widespread, with
1750 protein-truncating mutations in these genes having
been identified (see the Breast Cancer Information Core
[BIC] Web site). Some women found to carry such mu-
tations undergo prophylactic mastectomy and/or oopho-
rectomy, because their cancer risk is extremely high. How-
ever, although it is very clear that mutations in these genes,
segregating within these types of families, confer a sub-
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Table 1
Previously Published Breast and Ovarian Cancer Risks Associated with Mutations in BRCA1 and BRCA2
FAMILY ASCERTAINMENTa
BREAST CANCER RISK
(95% CI) AT
(%)
OVARIAN CANCER RISK
(95% CI) AT
(%)
REFERENCEAge 50 Years Age 70 Years Age 50 Years Age 70 Years
BRCA1:
Multiple-case families with Br/Ov 73 (49–87) 87 (72–95) 29 (16–40) 44 (28–56) Ford et al. 1994
Multiple-case families with Br/Ov 51 85 23 63 Easton et al. 1995
Multiple-case families with Ov 39 72 17 53 Antoniou et al. 2000
Hospital-based Ov cases 34 (17–60) 50 (26–82) 21 (8–47) 68 (36–94) Antoniou et al. 2000
Hospital-based Ashkenazi Jewish Br casesb 60 Warner et al. 1999
Hospital-based Ashkenazi Jewish Br casesb 46 (31–80) Satagopan et al. 2001
Population-based Br cases 32 (2–62) 47 (5–82) 11 (1–74) 36 (4–99) Anglian Breast Cancer Study Group 2000
Population-based Ov cases 13 30 5.4 15 Risch et al. 2001
BRCA1 and BRCA2:
Population-based Br cases 10 (0–24) 40 (16–64) Hopper et al. 1999
Unaffected Ashkenazi Jewish womenc 33 (23–44) 56 (40–73) 7 (2–14) 16 (6–28) Struewing et al. 1997
BRCA2:
Multiple-case families with Br/Ov 28 (9–44) 84 (43–95) .4 (0–1) 27 (47) Ford et al. 1998
Multiple-case Ov families 19 71 1 31 Antoniou et al. 2000
Hospital-based Ashkenazi Jewish Br casesd 28 Warner et al. 1999
Hospital-based Ashkenazi Jewish Br casesd 26 (14–50) Satagopan et al. 2001
Population-based Br casese 17 (9–26) 37 (22–54) Thorlacius et al. 1998
Population-based Br cases 18 (2–32) 56 (5–80) 3 (0–19) 10 (1–55) Anglian Breast Cancer Study Group 2000
Population-based Ov cases 3.6 8.8 1.6 4.5 Risch et al. 2001
a Br p breast cancer; Ov p ovarian cancer
b Carrying 185delAG and 5382insC.
c Carrying 185delAG, 5382insC, and 6174delT.
d Carrying 6174delT.
e Carrying 999del5.
stantial risk of both breast and ovarian cancer, the same
may not apply to mutations detected in other settings,
such as in families with less-extreme cancer histories or
in incident cases, even those of early onset.
Several approaches have been used to estimate the av-
erage age-specific cumulative cancer risks, or penetrance,
associated with mutations in BRCA1 and BRCA2. Early
estimates applied the maximum-LOD-score (or linkage)
method to multiple-case families collected for linkage
studies for the identification of disease loci (Easton et al.
1993; Clerget-Darpoux 2001). Subsequent penetrancees-
timates have used the incidence of cancer in the relatives
of mutation-carrying index case patients from case series
unselected for family history. Analytically, these are the
same method (i.e., a type of segregation analysis) applied
with different corrections for family ascertainment. Both
should give consistent estimates of penetrance, provided
that the same penetrance function applies to all carriers.
Different estimates will arise, however, either if the pen-
etrance is mutation specific or if the penetrance is mod-
ified by other risk factors, genetic or environmental, that
aggregate in families. Either of these phenomena would
lead to a higher actual penetrance for mutations segre-
gating in multiple-case families than for mutations seg-
regating in the population as a whole. Some authors (e.g.,
Begg 2002) have described the penetrance estimates de-
rived in this way as biased (Begg 2002). This is correct
in the sense that they do not reflect the average risks to
all carriers in the population. In practice, a counsellor is
rarely interested in the risks to the “average” carrier.
Virtually all genetic testing is conducted on women in
families with multiple cases of the disease—the types of
families from which the original penetrance estimates
were derived. Some women are tested on the basis of
weaker family histories or on the basis of having early-
onset disease; risk estimates derived by studying the can-
cer incidence in relatives of population-based series of
women with breast or ovarian cancer may then be more
appropriate.
Published penetrance estimates are summarized in ta-
ble 1. Breast and ovarian cancer risk estimates are gen-
erally higher in studies that are based on multiple-case
families (Ford et al. 1994, 1998; Easton et al. 1995)
than in those that are based on unselected series (Thor-
lacius et al. 1998; Hopper et al. 1999; Warner et al.
1999; Anglian Breast Cancer Study Group 2000). An-
other study, based on the family histories of 120 Ash-
kenazi Jewish volunteers in whom one of three different
founder mutations common to this population had been
identified, also reported lower penetrance estimates than
reports based on multiple-case families (Struewing et al.
1997). These penetrance estimates are averages over the
mutations segregating in the families in which mutations
have been identified. There are, however, data to sup-
port the hypothesis of allelic risk heterogeneity, such
that different mutations confer different risks. Specifi-
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cally, BRCA2 mutations that occur in families with one
or more cases of ovarian cancer tend to cluster in a central
portion of the gene, termed the “ovarian cancer cluster
region” (Gayther et al. 1997; Thompson and Easton
2001). A study of Breast Cancer Linkage Consortium
(BCLC) families has shown that mutations in the ovar-
ian cancer cluster region are associated with both a low-
er risk of breast cancer (relative risk [RR] 0.63) and a
higher risk of ovarian cancer (RRp 1.9), as compared
to mutations outside this region. Another study, based
on probands with ovarian cancer, found that theBRCA2-
associated breast cancer risk was associated only with
mutations outside the ovarian cancer cluster region
(Risch et al. 2001). Evidence for a genotype-phenotype
correlation in BRCA1 has also been found. Gayther et
al. (1995) have found that the risk of ovarian cancer
relative to the risk of breast cancer was higher in fami-
lies with protein-truncating mutations in the first two-
thirds of the gene than in families with protein-trun-
cating mutations in the last one-third of the gene. More
recently, Thompson and Easton (2002) have found that
mutations in a central region of BRCA1 were associated
with a lower risk of breast cancer, and Risch et al.
(2001) have reported that the risk of breast cancer in-
creases with mutation position, from 5′ to 3′.
Penetrance estimates based on multiple-case families
may be inappropriate for the counselling of women
without a strong family history of disease who have
been found to carry a germline mutation in BRCA1
or BRCA2. Although estimates based on mutation
testing in case series unselected for family history are
more appropriate in this context, published estimates
from individual studies have lacked precision, with
most studies having identified a few dozen mutations
at most. To improve the precision of penetrance esti-
mates based on unselected case series, we have com-
bined data from a large number of such studies into
a formal meta-analysis. This combined data set has
also allowed us to examine variations in penetrance
by type of mutation, type and age at diagnosis of index
case, birth cohort, and study center.
Subjects and Methods
Studies
Studies were eligible for this meta-analysis if all of the
following criteria were met: (1) The study was based on
mutation testing of a series of index cases either of female
or male breast cancer or of invasive epithelial ovarian
cancer. (2) Index cases were sampled independently of
family history (although they may have been selected by
age at diagnosis or ethnic group). (3) Index cases had
been tested for BRCA1 and/or BRCA2 mutations by a
systematic screen conducted independently of family his-
tory (mutation screening may have been of the entire cod-
ing sequence, of some part of the sequence, or of specific
founder mutations). (4) Enumeration of at least all first-
degree relatives of identified mutation carriers was avail-
able, along with ages at diagnosis of breast and ovarian
cancers and ages at last observation.
Potentially eligible studies were identified by a liter-
ature search using Medline (National Library of Med-
icine) and by personal contact through the BCLC. We
contacted 21 research groups, in total, that we believed
to have data from one or more relevant studies, and we
received data from 15. Participating investigators were
asked to provide details on all recorded members of
families in which the index case patient was found to
have a BRCA1 or BRCA2 mutation. These details in-
cluded date of birth, date of or age at diagnosis of any
breast or ovarian cancer, and age at death or age at last
observation. Data on cancers other than breast or ovar-
ian cancer were sometimes also available but were not
used in the present analysis. Investigators were also
asked to provide details of each mutation identified.
Details of the studies included are given in table 2.
Of the 22 studies included, 16 were conducted by
ascertainment of female breast cancer index cases, 2
were conducted by ascertainment of male breast can-
cer cases, and 4 were conducted by ascertainment of
ovarian cancer cases. Of the studies based on breast
cancer index cases, 10 restricted ascertainment by age
at diagnosis; in 9 of these, the upper limit for age at
diagnosis was 50 years. None of the studies based
on either male breast cancer index cases or ovarian
cancer index cases imposed a restriction on age at diag-
nosis. Sixteen of the studies ascertained cases through
a population-based cancer registry, whereas the remain-
der were based on unselected, hospital-based series. The
recruitment method for the studies varied widely. Most
studies obtained a blood sample and family-history data
simultaneously, but some studies collected a blood sam-
ple first and then retrospectively obtained family-history
data on mutation carriers whereas others obtained fam-
ily history data first and collected a blood sample later.
Furthermore, in some studies, not all available blood
samples were analyzed.
Mutations were included in the present analysis if they
were “pathogenic” according to the generally accepted
criteria (see the BIC Web site)—that is, frameshift or non-
sense mutations, splice-site mutations predicted to cause
aberrant splicing, large deletions or duplications, and mis-
sense mutations classified as such by BIC. In practice, the
last group included only mutations in the ring-finger do-
main of BRCA1. In-frame deletions and known poly-
morphisms or “unclassified variants” were not included.
A variety of mutation-screening techniques was used by
the studies. Of the studies, 14 screened for mutations in
both genes, 6 screened for mutations in BRCA1 only, and
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2 screened for mutations in BRCA2 only. Six studies in-
vestigated specific founder mutations (in the Ashkenazi
Jewish, Icelandic, and Polish populations), whereas the
remaining 16 studies screened the coding sequence of ei-
ther or both genes.
Statistical Methods
Kaplan-Meier estimation.—The cumulative probabili-
ties of breast and ovarian cancer in mothers and sisters
of BRCA1- and BRCA2-mutation carriers were estimated
using the Kaplan-Meier product-limit method, using the
program Stata (version 7). For this analysis, censoring age
was the age at breast cancer diagnosis, age at ovarian
cancer diagnosis, age at last follow-up, or age 70 years,
whichever occurred first. SEs and confidence limits were
obtained using Greenwood’s formula.
Penetrance estimation.—We used the information on
disease occurrence in relatives of mutation-positive index
case patients to estimate age-specific breast and ovarian
cancer incidences in mutation carriers by maximum like-
lihood, using modified segregation analyses implemented
in Mendel (Lange et al. 1988; Antoniou et al. 2001). This
is essentially the same methodology and software as that
used for penetrance analysis in multiple-case families (but
with a different ascertainment correction). Relatives were
assumed to be followed from age 20 years and to be
censored at the age at first cancer diagnosis, at the age at
death, at the age at last follow-up, or at age 70 years,
whichever came first. Information on mutation status in
relatives was incorporated when available. Females born
before 1890 were excluded from the analyses. Individuals
with no age information (608 females from entire data
set) or no year of birth (53 females) were censored at age
0 years. To correct for ascertainment, we maximized the
conditional likelihood of the pedigree given the pheno-
typic and genotypic information of the index case.
The main analyses were based on the fitting of fixed
age-specific incidence rates for carriers. Initially, these
rates were assumed to be independent of country of origin
or year of birth, but we then explored variation in rates
according to these covariates. Breast cancer incidence in
carriers was assumed to follow ,l (t)p l (t) exp [g (t)]0
where is the background incidence for England andl (t)0
Wales (1973–77) and is the age-specific RR ofexp [g(t)]
breast cancer in carriers as compared to population rates.
The ovarian cancer incidences were assumed to follow a
similar model. Conditional on the genotype, the proba-
bility of developing breast cancer was assumed to be in-
dependent of the probability of developing ovarian cancer.
We estimated the age-specific log(RR) parameters forg(t)
five age groups: 20–29, 30–39, 40–49, 50–59, and 60–69
years. We then fitted models with carrier incidences pa-
rameterized in terms of rate ratios relative to country-,
age-, and period-specific incidences. In all analyses, can-
cer incidences in noncarriers were assumed to follow
country- and cohort-specific rates (Waterhouse et al.
1976, 1982; Muir et al. 1987; Parkin et al. 1992, 1997).
To test for differences in incidences among different
subgroups, we fitted models in which we added a sub-
group-specific log(RR) parameter. For example, to test
for differences among centers, we fitted models in-
cluding the five age-specific log(RR) estimates (for all
centers) but also allowed an additional center-specific
log(RR) (constant over age). A likelihood-ratio test
was then used to test for heterogeneity of risk among
centers. Similar tests were used to explore variations
in incidences by year of birth, type of mutation, and
type and age of index case patient. Trend tests were
used to test whether the log(RR) estimates increased
or decreased significantly with age.
To construct CIs for the log(RR) estimates, we as-
sumed that the parameters were asymptotically normally
distributed with the covariance matrix given by inverting
the information matrix. Cumulative risk or penetrance
and 95% CIs were calculated from the cumulative in-
cidence , where , where isnl(t) L(t)p  i t exp (b ) ik k k kkp1
the incidence in noncarriers in the kth age band of length
and is the ln(RR) in the kth age band. The variancet bk k
of the cumulative risk is given by the expression
n
2 2 ( )var[L(t)]p i t var(b ) exp 2b k k k k
kp1
n
1/22 i i t t [var(b )var(b )] exp (b ) exp (b )corr(b ,b ) , k j k j k j k j k j
!j k,kp1
and the cumulative risk is then given byF(t) F(t)p
, with a 95% CI of1 exp [L(t)] 1 exp {L(t)
. Uncertainty in RRs for factors with1.96 var[L(t)]}
more than two categories (e.g., center) is presented as
floating CIs (Easton et al. 1991).
Results
The 22 studies included in the present analysis screened
a total of 6,965 female breast cancer cases, 176 male
breast cancer cases, and 998 ovarian cancer cases and
identified 289 BRCA1- and 221 BRCA2-mutation car-
riers (table 2). Table 2 also shows the number of indi-
viduals eligible for each study, the number enrolled, and
the number of samples analyzed. However, estimation
of a response rate that is comparable across all studies
is not possible, because of the variety of protocols used
in recruitment and data gathering (see the “Subjects and
Methods” section). Family-history data were not avail-
able for 12 mutation carriers, leaving 280 families of
BRCA1-mutation carriers and 218 families of BRCA2-
mutation carriers in the present analysis. Among the
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Figure 1 Kaplan-Meier cumulative breast (upper lines) and
ovarian (lower lines) cancer probability in sisters (thick lines) and
mothers (thin lines) of BRCA1-mutation–carrying index case patients.
Figure 2 Kaplan-Meier cumulative breast (upper lines) and
ovarian (lower lines) cancer probability in sisters (thick lines) and
mothers (thin lines) of BRCA2-mutation–carrying index case patients.
first-degree relatives of BRCA1-mutation–positive index
case patients, 125 breast cancers and 41 ovarian cancers
were identified, and, among the first-degree relatives of
BRCA2-mutation–positive index case patients, 87 breast
cancers and 13 ovarian cancers were identified.
Kaplan-Meier Estimates
Figure 1 shows the age-specific cumulative probabil-
ities of breast and ovarian cancer in mothers and sis-
ters of BRCA1-mutation carriers, using Kaplan-Meier
estimation. The estimated cumulative risks of breast
cancer by age 70 years were 29% (95% CI 23%–35%)
in mothers and 42% (95% CI 30%–56%) in sisters;
the corresponding cumulative risks of ovarian cancer
were 15% (95% CI 10%–21%) in mothers and 14%
(95% CI 7.5%–24%) in sisters. Although the estimated
breast cancer risks are higher in sisters than mothers
at all ages, the difference in risks was not statistically
significant (log-rank for breast cancer; log-Pp .056
rank for ovarian cancer).Pp .75
Figure 2 shows the corresponding Kaplan-Meier es-
timates for mothers and sisters of BRCA2-mutation
carriers. The cumulative risks of breast cancer by age
70 years were 19% (95% CI 14%–26%) in mothers
and 25% (95% CI 18%–34%) in sisters, whereas the
cumulative risks of ovarian cancer were 5.1% (95% CI
2.7%–9.6%) in mothers and 4.5% (95% CI 1.7%–
12%) in sisters. Again, the differences in risks between
mothers and sisters were not statistically significant for
either cancer ( for breast cancer; forPp .12 Pp .53
ovarian cancer).
Average Penetrance Estimates
For the main analysis, we assumed that the age-specific
incidences were the same for all mutation carriers and
that incidences in noncarriers were country and birth-
cohort specific. The RRs of breast and ovarian cancer
in BRCA1- and BRCA2-mutation carriers, compared to
population rates for England and Wales in 1973–77, are
shown in table 3. For BRCA1, the breast cancer RR
increased to 33 in the 30–39-years age group and de-
creased with age thereafter (P trend .012), whereas the
ovarian cancer RR estimates showed no apparent trend
with age. The estimated breast cancer RR to BRCA2-
mutation carriers was 19 in the 20–29-years age group
and fell to ∼10 in older-age groups (P trend .98). Ovarian
cancer RRs for BRCA2-mutation carriers were only es-
timated for ages 40 years, because there were no ovar-
ian cancer cases diagnosed at !40 years of age in the
first-degree relatives of BRCA2-mutation carriers. The
RR increased to a maximum of 19 in the 50–59-years
age group and then decreased.
The corresponding age-specific incidences are shown in
table 4, and the cumulative cancer risks (penetrances) are
shown in figures 3 and 4. The breast cancer incidence in
BRCA1-mutation carriers increased with age up to age
45–49 years but remained roughly constant thereafter.
The ovarian cancer rates were low below age 30 years
and rose steeply with age thereafter, to ∼2% per annum,
only slightly less than the breast cancer rates. The breast
cancer incidence in BRCA2-mutation carriers increased
progressively with age, whereas the ovarian cancer inci-
dence increased up to age 55–59 years and then decreased
slightly. The cumulative breast cancer risk by age 70 years
in BRCA1-mutation carriers was estimated to be 65%
(95% CI 51%–75%), and the ovarian cancer risk was
estimated to be 39% (95% CI 22%–51%). For BRCA2-
mutation carriers, the cumulative breast cancer risk by
age 70 years was estimated to be 45% (95% CI 33%–
54%), and that for ovarian cancer was estimated to be
11% (95% CI 4.1%–18%).
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Table 3
RRs of Breast and Ovarian Cancer in Mutation Carriers
AGE GROUP
RRa (95% CI) OF CANCER
FOR CARRIERS OF MUTATIONS IN
BRCA1 BRCA2
Breast
Cancer
Ovarian
Cancer
Breast
Cancer
Ovarian
Cancer
20–29 years 17 (4.2–71) 1.0 19 (4.5–81) 1.0
30–39 years 33 (23–49) 49 (21–111) 16 (9.3–29) 1.0
40–49 years 32 (24–43) 68 (42–111) 9.9 (6.1–16) 6.3 (1.4–28)
50–59 years 18 (11–30) 31 (14–66) 12 (7.4–19) 19 (9.0–41)
60–69 years 14 (6.3–31) 50 (22–114) 11 (6.3–20) 8.4 (2.2–32)
a As compared to incidences for England and Wales in 1973–77.
Table 4
Estimated Breast and Ovarian Cancer Incidence (%) in Mutation
Carriers
AGE GROUP
ESTIMATED CANCER INCIDENCE
FOR CARRIERS OF MUTATIONS IN
BRCA1 BRCA2
Breast
Cancer
Ovarian
Cancer
Breast
Cancer
Ovarian
Cancer
20–24 years .02 .001 .02 .001
25–29 years .11 .002 .12 .002
30–34 years .74 .18 .36 .004
35–39 years 1.59 .28 .78 .01
40–44 years 2.92 .87 .91 .08
45–49 years 4.28 1.49 1.34 .14
50–54 years 2.65 .96 1.76 .60
55–59 years 3.01 1.19 2.00 .75
60–64 years 2.70 2.26 2.17 .38
65–69 years 2.96 2.49 2.38 .42
Analysis by Center
We investigated potential heterogeneity of risk among
centers by fitting models with additional center-specific
RR parameters. For BRCA1, we grouped the U.K., Ca-
nadian, Polish, and other centers (43, 124, 48, and 65
families, respectively). RRs by center are shown in table
5. The estimated cancer risks were somewhat lower in
the Canadian and Polish families than in the U.K. and
other families, but there was no significant evidence of
heterogeneity ( ).Pp .32
For BRCA2, we grouped the U.K., Canadian, Ice-
landic, and other centers (44, 63, 69, and 42 families,
respectively). Again, there was no significant evidence of
heterogeneity (P p .13). The estimated breast cancer
risks for Canadian centers were lower than for the U.K.
and Icelandic centers (RRp 0.53), and the ovarian can-
cer risk was higher (RR p 3.1). There was also some
suggestion of higher cancer risks for “other centers” as
compared to the U.K. center (RRp 1.4 for breast cancer,
and RR p 4.2 for ovarian cancer).
Effect of Year of Birth
We investigated the effect of birth cohort on breast
and ovarian cancer risks by fitting models with addition-
al parameters for birth cohorts (before 1920, 1920–39,
1940–59, and from 1960 onward for breast cancer; be-
fore 1920, 1920–39, and from 1940 onward for ovarian
cancer). For BRCA1-mutation carriers, we found higher
risks for both breast and ovarian cancer ( andPp .011
, respectively) in more-recent birth cohortsPp .0013
(table 5). The RR of breast cancer in BRCA2-mutation
carriers also increased with more-recent birth cohort (ta-
ble 5), but not significantly ( ). There were tooPp .16
few ovarian cancer cases among the first-degree relatives
of the index case patients to assess cohort effects on
ovarian cancer risk in BRCA2-mutation carriers.
Effect of Type of Index Case
One hundred seventeen families were ascertained
through a BRCA1-mutation–carrying index case pa-
tient with ovarian cancer, and 163 families were as-
certained through a BRCA1-mutation–carrying index
case patient with breast cancer. We fitted models, add-
ing an RR parameter for type of index case (table 5).
The breast cancer risk for BRCA1-mutation carriers
ascertained through an ovarian cancer index case was
lower than that for carriers ascertained through a breast
cancer index case (RR p 0.60 [95% CI 0.38–0.94];
cumulative risk by age 70 years 56% vs. 72%). The
ovarian cancer risks, however, did not differ significantly
by type of index case (RR p 0.86 [95% CI 0.42–1.8]).
Families ascertained through a breast cancer case were
subdivided further by age at diagnosis of the index case.
The breast and ovarian cancer risk estimates were higher
in the families of the early-onset index cases, although
only the breast cancer effect was significant (table 5)
(breast cancer RR p 2.2 [95% CI 1.4–3.3]; ovarian
cancer RR p 1.8 [95% CI 0.82–4.0]). On the basis of
this analysis, the breast cancer risk forBRCA1-mutation
carriers for families ascertained through early-onset in-
dex cases was estimated to be 87% (95% CI 67%–95%)
by age 70 years, and the ovarian cancer risk was esti-
mated to be 51% (95% CI 9.1%–73%), compared to
61% (41%–74%) and 32% (11%–49%) for families
ascertained through an older index case patient. The risk
estimates for older index case patients with breast cancer
were comparable to those for ovarian cancer index case
patients (54% and 36%).
Fifty BRCA2-mutation–positive families were ascer-
tained through an ovarian cancer index case, 148 were
ascertained through a female breast cancer index case,
and 20 were ascertained through a male breast cancer
index case. Of the female index case patients, 46 received
a diagnosis at !35 years of age, and 102 received a di-
agnosis at 35 years of age. The estimated breast cancer
risk in carriers ascertained through a breast cancer index
case was higher than in those ascertained through an ovar-
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Figure 3 Cumulative risk of breast () and ovarian ( ) cancer
in BRCA1-mutation carriers.
Figure 4 Cumulative risk of breast () and ovarian ( ) cancer
in BRCA2-mutation carriers.
ian cancer index case (RRp 0.42 [95% CI 0.20–0.88]).
Conversely, the ovarian cancer risk was higher in the fam-
ilies ascertained through an ovarian cancer index case
(RRp 2.4 [95% CI 0.74–8.1]). There was no evidence
of a difference in risk according to whether the index
case patient with breast cancer was a male or a female
who received a diagnosis at 35 years of age (RRp 1.3
[95% CI 0.65–2.7]). Among carriers ascertained through
a female breast cancer index case, there was no significant
difference in the breast cancer risks according to whether
the index case was diagnosed at !35 years of age or at a
later age (RRp 1.2 [95% CI 0.57–2.5]; cumulative risks
by age 70 years 55% [16%–76%] vs. 49% [32%–61%]),
but there was some evidence of higher ovarian cancer risk
for families ascertained through early-onset breast cancer
cases (RR p 13 [95% CI 2.4–70]; cumulative risks by
age 70 years 35% [0.61%] vs. 3% [0–7%]).
Since ascertainment criteria varied by center, we also
fitted models in which RRs for center and type of index
case were fitted simultaneously. Under this model, the
breast cancer risk for BRCA1-mutation carriers ascer-
tained through index cases diagnosed as breast cancer at
!35 years of age remained higher than that for carriers
whose diagnosis was given at later ages (RRp 2.2 [95%
CI 1.2–4.2]). Some suggestion of a higher ovarian cancer
risk among carriers ascertained through ovarian cancer
index cases, not evident from the univariate analysis,
emerged when center was taken into account (RRp 1.9
[95% CI 0.67–5.2]). We were unable to fit the effects of
index case and center for BRCA2. These effects were con-
founded because all the ovarian cancer index cases were
from one center (Canada).
We also fitted models allowing for both type of index
case and year of birth. The estimated effects that type
of index case had on both breast and ovarian cancer
risk were similar to those estimated previously. Thus,
the RR based on breast cancer cases diagnosed at !35
years of age, relative to those diagnosed at later ages,
was 1.9 (95% CI 1.1–3.3), whereas the RR for mutation
carriers ascertained through an ovarian cancer index
case was 0.84 (95% CI 0.51–1.37). Adjustment for type
of index case did not materially affect the year of birth
effect: the estimated RRs for mutation carriers born in
the 1920–39, 1940–59, and 1960-onward cohorts were
1.8 (95% CI 0.88–3.6), 2.5 (1.2–5.3), and 4.9 (1.4–18),
respectively. We fitted similar models for BRCA2, but
the RRs for both the type-of-index-case effect and the
birth-cohort effect were similar to those when each effect
was considered individually.
Center- and Cohort-Specific Incidence Models
The apparent variation in incidence by center and
birth cohort may reflect variations in population-spe-
cific incidence rates. We therefore also performed
analyses in which we estimated the age-specific RRs
in carriers relative to population- and cohort-specific
incidence rates. The RRs estimated in these models
were very similar to those estimated in the analyses
that assumed a constant background incidence rate
(table 6). We then fitted models allowing for hetero-
geneity between center and birth cohort. The RR es-
timates by center were very similar to those for the
fixed incidences models, with no significant evidence
for heterogeneity of risk by center for either gene.
The cohort effects were slightly less marked than the
fixed incidence rate model. For BRCA1, the breast can-
cer RR estimates for the three later birth cohorts, relative
to the before-1920 cohort, were as follows: 1920–39,
2.6 (95% CI 1.3–5.2); 1940–59, 3.1 (95% CI 1.5–6.5);
and 1960 onward, 6.2 (95% CI 1.7–22.1). The ovarian
cancer RRs for the 1920–39 and 1940–59 birth cohorts,
compared to the before-1920 cohort, were estimated as
9.8 (95% CI 2.6–36.6) and 7.6 (95% CI 1.9–30.8), re-
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Table 5
RRs for Mutation Carriers, as Compared to Baseline, for Models Allowing for Center, Type-of-Index-Case,
and Year-of-Birth Effects
CENTER
RR (95% FLOATED CI) FOR CARRIERS OF MUTATIONS IN
BRCA1 ( )Pp .32 BRCA2 ( )Pp .13
Breast Cancer Ovarian Cancer Breast Cancer Ovarian Cancer
United Kingdoma 1.0 (.55–1.8) 1.0 (.41–2.4) 1.0 (.69–1.4) 1.0 (.33–3.1)
Canada .51 (.36–.71) .34 (.19–.59) .53 (.30–1.0) 3.1 (1.3–7.1)
Poland .47 (.28–.78) .40 (.18–.90) … …
Iceland … … 1.0 (.69–1.4) 1.0 (.33–3.1)
Other .69 (.44–1.1) .52 (.25–1.1) 1.4 (.77–2.6) 4.2 (1.2–14)
TYPE OF INDEX CASE
RR (95% FLOATED CI) FOR CARRIERS OF MUTATIONS IN
BRCA1 ( )Pp .015 BRCA2 ( )Pp .01
Breast Cancer Ovarian Cancer Breast Cancer Ovarian Cancer
Breast cancer at 35 yearsa 1.0 (.68–1.5) 1.0 (.53–1.9) 1.0 (.68–1.5) 1.0 (.42–2.4)
Breast cancer at !35 years 2.2 (1.4–3.3) 1.8 (.82–4.0) 1.2 (.57–2.5) 14 (3.8–53)
Male breast cancer … … 1.3 (.65–2.7) 1.8 (.92–3.6)
Ovarian cancer .83 (.59–1.2) 1.1 (.69–1.8) .45 (.23–.89) 6.5 (2.1–21)
YEAR OF BIRTH
RR (95% FLOATED CI) FOR CARRIERS OF MUTATIONS IN
BRCA1 ( )Pp .00001 BRCA2 ( )Pp .16
Breast Cancer Ovarian Cancer Breast Cancer Ovarian Cancer
Before 1920a 1.0 (.53–1.9) 1.0 (.27–3.7) 1.0 (.60–1.7) …
1920–39 2.7 (1.9–3.8) 12 (7.3–18) 1.2 (.71–1.9) …
1940–59 3.7 (2.6–5.1) 9.5 (4.9–19) 2.1 (1.2–3.6) …
1960 onward 7.7 (2.6–23) … 4.8 (1.0–23) …
NOTE.—P values are from comparison of the fitted model with that of the basic model. Age-specific RRs
for each of these models are not shown but in all cases were similar to the estimates for the basic model
(table 4).
a Baseline category.
Table 6
RR Estimates for Mutation Carriers, Based on Country- and Cohort-
Specific Background Rates
AGE GROUP
RR ESTIMATES (95% FLOATED CI)
FOR CARRIERS OF MUTATIONS IN
BRCA1 BRCA2
Breast
Cancer
Ovarian
Cancer
Breast
Cancer
Ovarian
Cancer
20–29 years 18 (4.4–75) 1.0 19 (4.4–82) 1.00
30–39 years 36 (25–52) 38 (17–88) 16 (9.3–29) 1.00
40–49 years 31 (25–52) 61 (38–99) 9.5 (5.9–15) 6.3 (1.4–28)
50–59 years 16 (9.6–27) 30 (14–65) 11 (6.6–17) 19 (9.1–41)
60–69 years 11 (5.0–25) 48 (22–109) 9.2 (5.1–17) 7.3 (1.8–30)
spectively. There were no ovarian cancer cases in rela-
tives born after 1960, so no RR parameter was estimated
for this cohort. Both effects remained highly significant.
For BRCA2, the corresponding breast cancer RRs were
0.94 (95% CI 0.49–1.8), 1.4 (95% CI 0.65–3.0), and
3.6 (95% CI 0.65–19), respectively. As with the fixed
incidence rate model, the cohort effects were not sig-
nificant for BRCA2-mutation carriers ( ). TherePp .26
were too few ovarian cancer cases among the first-degree
relatives of the index case patients to assess cohort effects
on ovarian cancer risk in BRCA2-mutation carriers.
Effect of Mutation Position
We investigated the possibility of allelic heterogeneity
in risk by classifying mutations according to their po-
sition and by fitting models comparable to the previous
BCLC analyses (Thompson and Easton 2001). Families
with the BRCA1 C61G missense mutation were ex-
cluded from the present analysis. BRCA1 mutations
were categorized into three groups as defined previously:
nucleotides 1–2400 (137 index cases), 2401–4184 (55
index cases), and 4185 onward (88 index cases). The
RR of breast cancer for mutations in the central region
as compared to that for mutations in the 5′ region was
estimated to be 0.93, and that for mutations in the 3′
region was estimated to be 1.4; the corresponding risks
for ovarian cancer were 1.8 and 1.1. These models did
not fit significantly better than the null model.
BRCA2 mutations were divided into those within the
ovarian cancer cluster region (nucleotides 3059–6629
[97 index cases]) and those outside the ovarian cancer
cluster region (mutations at all other nucleotides [121
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index cases]). We fitted models in which the breast and
ovarian cancer risks were allowed to vary between the
two regions. The estimated breast cancer risk was lower
among carriers of mutations in the ovarian cancer cluster
region as compared to mutations outside the ovarian
cancer cluster region (RR p 0.57 [95% CI 0.32–1.0]).
The corresponding ovarian cancer RR was 2.1 (95% CI
0.62–7.0).
Discussion
In this meta-analysis, we have used data from 22 studies
that have tested patients with breast or ovarian cancer
who were unselected for family history of germline mu-
tations in BRCA1 and/or BRCA2 as a basis for the es-
timation of breast and ovarian cancer incidences and
cumulative risks in mutation carriers. We are aware of
a few studies that could not be included in the present
analysis, and, undoubtedly, there are other such studies
ongoing. Nevertheless, this overview represents the large
majority of the available data, and, especially given the
costs of such studies, it seems unlikely that much greater
precision will be available in the near future from studies
of this design.
The major perceived strength of this approach, as
compared with the linkage approach based on multi-
ple-case families, is that it produces estimates that are
less susceptible to the effects of other familial risk fac-
tors and mutation-specific differences in risk. Although
this is true, it is important to note that the families
that we have analyzed were still selected on the basis
of an affected index case patient, so that, in the pres-
ence of modifying risk factors, the estimated risks will
be higher than the risks to a completely unselected
mutation carrier. Nevertheless, since one affected rel-
ative would usually represent an absolute minimum
criterion for genetic testing, it seems unlikely that risk
estimates that lie much outside this range will be
needed in any practical situation.
There are two other important advantages of this ap-
proach. First, it provides estimates for site-specific cancer
risks that are largely uncorrelated, whereas the breast
and ovarian cancer risk estimates derived by the maxi-
mum-LOD-score approach in multiple-case families tend
to be strongly correlated. Second, relative to the maxi-
mum-LOD-score approach, the estimates at early ages,
when the risks are low, are more precise. A major dis-
advantage of this approach is that the prevalence of mu-
tations in unselected case series is low and, therefore,
very large numbers of cases need to be tested to provide
precise estimates. Thus, the studies in the present analysis
included 18,000 index cases, yielding 282 BRCA1 and
218 BRCA2 mutations. Despite this, the width of many
of the confidence limits still exceeds 10%.
Another important issue is the accuracy of reporting
of family history. Although some of the studies did at-
tempt to confirm cancer diagnoses in relatives, this was
not always possible, and only three studies were able
to identify routinely all cancer diagnoses in relatives
through national records. In an attempt to minimize the
effects of inaccurate reporting, we restricted our main
analyses to first-degree relatives. Previous studies (e.g.,
Claus et al. 1998) have found that reporting of cancer
in more-distant relatives is less accurate. Although data
on more-distant relatives were easily incorporated in the
analysis, we found that some of the penetrance estimates
were higher. This suggests either inaccurate reporting of
cancer diagnoses or incompleteness in the enumeration
of relatives that correlated with the extent of family
history.
The techniques used for mutation detection in the dif-
ferent studies—and, therefore, their sensitivity to detect
mutations of different types—varied widely. Certain stud-
ies tested only for specific founder mutations (T300G,
185delAG, 4158delA, and 5382insC inBRCA1; 999del5
and 6174delT in BRCA2), but these mutations still rep-
resent a minority of the total set. Most of the groups
used screening techniques that are most sensitive for small
deletions and insertions, so these will be overrepresented
in the data set; however, these are the mutations that
account for the majority of mutations in families with
linkage, and they represent the most important muta-
tion type encountered in genetic testing. Since we re-
stricted the present analysis to mutation types generally
regarded as pathogenic, almost all the mutations are
predicted to be protein truncating (the only exception
being the T300G mutation in the ring finger ofBRCA1).
Thus, although these results are likely to be applicable
generally to protein-truncating mutations, they will not
be applicable to missense changes.
In a small number of families, carrier status of relatives
was available, and we were able to incorporate this into
the analysis. In most cases, however, carrier status had
to be assigned probabilistically. The method relies on the
assumption of Mendelian segregation of the mutation—
which seems reasonable but also ignores the possibility
of new mutation events. However, few new mutations in
BRCA1 or BRCA2 have been reported, and the new-
mutation rate is generally assumed to be low.
Overall Estimates
The overall estimates confirm most of the qualitative
features, of age-specific risks in BRCA1- and BRCA2-
mutation carriers, that have been suggested from studies
based on multiple-case families or individual population
studies, but with much more precise quantification. Thus,
the average risks of both breast and ovarian cancer are
higher in BRCA1-mutation carriers than in BRCA2-mu-
tation carriers, but the difference is much more marked
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for ovarian cancer and for breast cancer at earlier ages
than for breast cancer at 150 years of age. The RR of
breast cancer inBRCA1-mutation carriers, relative to gen-
eral population rates, declines with age from 130-fold at
!40 years of age to 14-fold at 160 years of age; by con-
trast, the RR in BRCA2-mutation carriers is ∼11-fold in
all age groups at 140 years of age and is not significantly
higher at earlier ages. As a consequence of this, the in-
cidences in BRCA1-mutation carriers rise to a plateau of
∼3%–4% per annum in the 40–49-years age group and
are roughly constant thereafter, whereas theBRCA2 rates
show a pattern similar to that in the general population,
rising steeply up to age 50 years and more slowly there-
after.
Ovarian cancer risks in BRCA1-mutation carriers
were low (in absolute terms) at !40 years of age (no
cases at all were observed at !30 years of age). There-
after, the incidences were ∼1% at 40–59 years of age
and 2% at 160 years of age (the latter estimate is,
however, particularly imprecise, since there are rela-
tively few unaffected carriers in this age group). Ovar-
ian cancer risks in BRCA2-mutation carriers are, in
contrast, very low at !50 years of age but then in-
crease sharply in the 50–59-years age group, perhaps
declining somewhat thereafter. These differences in
age-specific risks are mirrored by other important dif-
ferences in the pathological characteristics of tumors
in carriers (e.g., the estrogen-receptor–negative status
of most breast tumors in BRCA1-mutation carriers
but not in BRCA2-mutation carriers) and must reflect
some important functional differences between the
two proteins.
Absolute versus Relative Risk Models—and Cohort
and Center Effects
We chose to model the BRCA1 and BRCA2 penetranc-
es primarily in terms of RRs compared to a single set of
background rates (those for England and Wales), thus
estimating a single set of incidences for carriers from all
populations. We also performed an alternative analysis in
which the penetrance was expressed in terms of RRs rel-
ative to the population-specific incidences (so that the
absolute risks would be higher in populations with higher
background incidence rates). Such a model may be more
appropriate if risks in carriers were modified by important
lifestyle risk factors to a similar (relative) extent as in
noncarriers. In fact, we found little evidence to favor one
model over the other. Although we did find some evidence
of variation in penetrance among populations, this did
not correlate directly with population rates—for example,
breast cancer risks were lower in families from the Polish
center than in those from the U.K. centers but were sim-
ilarly lower in families from the Canadian centers.
We found that year of birth had a marked effect on
breast cancer risk in BRCA1, with a slightly weaker
(and nonsignificant) effect in BRCA2-mutation carriers
and for ovarian cancer risk in BRCA1-mutation car-
riers. The breast cancer effect was slightly weaker when
analyses were performed relative to cohort-specific back-
ground rates but was still highly significant. Most of this
effect was due to a markedly lower risk in women born
before 1920. A possible explanation for this effect is the
incomplete reporting of cancers among women born in
this generation. In practice, the before-1920 birth cohort
is not relevant to current genetic counselling, and ex-
clusion of this birth cohort from the present analysis
made little difference to the overall penetrance estimates
(data not shown). There was also some evidence of a
higher breast cancer risk in the 1960-onward birth co-
hort. This result seems less likely to be due to the un-
derreporting of cancers in relatives. It could conceivably
reflect changing patterns of reproductive risk factors,
such as age at first pregnancy, breast feeding, or oral
contraceptive use. Changes in screening practices may
also account for some of the cohort effect. This will
require more-detailed investigation.
Type of Index Case
We found some evidence of variation in penetrance
estimates according to the type of index case. The breast
cancer risk estimates for both BRCA1- and BRCA2-
mutation carriers were higher when the index case was
a breast cancer case, rather than an ovarian cancer case,
and were markedly higher when the index case was a
breast cancer case diagnosed at !35 years of age. A sim-
ilar effect has been reported previously (Eccles et al.
1994). The ovarian cancer risks in BRCA1-mutation
carriers were also highest in families selected on the
basis of a breast cancer index case diagnosed at !35
years of age, but, for BRCA2-mutation carriers, the
risks were higher when based on ovarian cancer index
cases (albeit with wide confidence limits). Such differ-
ences in penetrance estimates are generally consistent
with the hypothesis that other genes modify risks in
carriers. Alleles conferring a higher risk of breast cancer
will be more frequent among index cases diagnosed at
earlier ages, leading to higher breast cancer risks in
carriers’ relatives. The more complicated pattern of
ovarian cancer risk in BRCA1-mutation carriers may
be explicable if some modifiers of breast cancer risk
also modified ovarian cancer risk. No genetic modifiers
have been definitively implicated yet, although several
have been suggested; these include, for breast cancer,
the lengths of triplet repeats in the androgen-receptor
(Rebbeck et al. 1999) and AIB1 (Rebbeck et al. 2001)
genes and polymorphisms in the progesterone-receptor
(Runnebaum et al. 2001) and (for BRCA2) RAD51
(Levy-Lahad et al. 2001) genes. Rare alleles at the
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HRAS1 minisatellite locus have been suggested to be
associated with ovarian cancer risk in BRCA1-muta-
tion carriers (Phelan et al. 1996).
Mutation-Specific Risks
Mutation-specific differences in risk have been sug-
gested for both BRCA1 and BRCA2 from differential
cancer risks in multiple-case families, and we were able
to test these hypotheses in this data set. In the case of
BRCA2, Thompson and Easton (2001) have found a
higher risk of ovarian cancer but a lower risk of breast
cancer in carriers of mutations in the ovarian cancer
cluster region. The RR estimates from the current data
set were of a similar magnitude (0.57 for breast cancer
and 2.1 for ovarian cancer), but neither was significant.
Furthermore, the ovarian cancer effect disappeared once
the 999del5 and 6174delT mutations were removed
from the analysis. In the case of BRCA1, Thompson and
Easton (2002) have found a lower risk of breast cancer
associated with mutations in a central region of the gene
(nucleotides 2401–4184), together with a lower risk of
ovarian cancer for mutations 3′ of nucleotide 4184. The
estimate RRs from our data set were in the same direc-
tion (and, in the case of the breast cancer risk, of a similar
magnitude) as those reported by Thompson and Easton
(2002), but neither effect was statistically significant. Al-
though the consistency of these results is reassuring, they
emphasize that detailed analyses of mutation-specific
risks can be achieved only through studies of multiple-
case families.
Conclusions
The present analysis has provided breast and ovarian
cancer risks in BRCA1- and BRCA2-mutation carriers
that are based on the majority of available data from
studies of mutation screening in series of patients with
breast and ovarian cancer who were unselected for fam-
ily history. It has confirmed that the lifetime risks based
on this design are lower than those based on high-risk
families, suggestive of some modification of risk by other
factors, but the differences are smaller than has been
suggested by some previous studies. The variation in
risks by type of index case and by age at diagnosis of
index case is also suggestive of risk modifiers. Risk es-
timates for counselling should take into account both
mutation status and family history, as well as other risk
factors once their effects become reliably known.
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